Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share of Common Stock (Tables)

Net Loss Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of Net Loss Per Share Basic and Diluted

The computation of net loss per share for the year ended December 31, 2019 and 2018 was as follows:

	2019			2018
Basic and diluted net loss per share:
Net loss	$	(3,357,876	)	$	(3,765,047	)
Deemed dividend related to the triggering of the full ratchet anti-dilution provision at fair value		(506,993	)		-
Net loss available to common shareholders		(3,864,869	)		(3,765,047	)

Weighted-average number of common shares-basic and diluted		5,525,635			5,332,141

Basic and diluted net loss per share	$	(0.70	)	$	(0.71	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The outstanding options and warrants to purchase common stock and the shares issuable under the 2017 and 2019 Senior Notes were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the periods are presented below:

	2019		2018
Stock options and purchase warrants		654,569		571,055
Senior convertible notes		60,883		17,531